Latest Content

Interim GLOVe trial results show that the frontline combination of glofitamab, lenalidomide, and venetoclax induces rapid, deep, and predominantly MRD-negative remissions in high-risk mantle cell lymphoma with manageable toxicity.

Federal policy changes, the push for fair pricing, and growing competition in the drug pipeline were major topics at this year’s meeting.

Trump secures new pricing deals with 9 drugmakers, advancing his effort to align US drug costs with Europe and expand direct-to-consumer purchasing.

The approval was based on the pivotal phase 3 FIBRONEER-ILD trial, in which nerandomilast slowed lung function decline in PPF and had similar discontinuation rates to placebo.

The top Managed Care Cast episodes explored wellness visits, weight loss drug access, neurospine care, public health policy, and ketamine-assisted therapy.

A new study links immune markers and coping patterns to disease control in adolescents with chronic urticaria.

A nationwide Danish cohort study reports cardiovascular events up to 1 year after infection, comparable to that observed with influenza.

Genetics played a major role in predicting worsening LVEF, progressing to a dilated cardiomyopathy phenotype, and a combined end point of both.

This year's top ovarian cancer article highlighted gaps in physician knowledge of genetic testing that may affect patient care.